1. Home
  2. HSHP vs ADCT Comparison

HSHP vs ADCT Comparison

Compare HSHP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSHP
  • ADCT
  • Stock Information
  • Founded
  • HSHP 2021
  • ADCT 2011
  • Country
  • HSHP Bermuda
  • ADCT Switzerland
  • Employees
  • HSHP N/A
  • ADCT N/A
  • Industry
  • HSHP
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSHP
  • ADCT Health Care
  • Exchange
  • HSHP Nasdaq
  • ADCT Nasdaq
  • Market Cap
  • HSHP 282.3M
  • ADCT 285.2M
  • IPO Year
  • HSHP 2023
  • ADCT 2020
  • Fundamental
  • Price
  • HSHP $7.09
  • ADCT $3.02
  • Analyst Decision
  • HSHP
  • ADCT Strong Buy
  • Analyst Count
  • HSHP 0
  • ADCT 5
  • Target Price
  • HSHP N/A
  • ADCT $8.00
  • AVG Volume (30 Days)
  • HSHP 117.2K
  • ADCT 377.1K
  • Earning Date
  • HSHP 01-01-0001
  • ADCT 11-07-2024
  • Dividend Yield
  • HSHP 6.06%
  • ADCT N/A
  • EPS Growth
  • HSHP N/A
  • ADCT N/A
  • EPS
  • HSHP 0.58
  • ADCT N/A
  • Revenue
  • HSHP $112,303,000.00
  • ADCT $70,717,000.00
  • Revenue This Year
  • HSHP $284.85
  • ADCT $6.94
  • Revenue Next Year
  • HSHP $16.28
  • ADCT $14.83
  • P/E Ratio
  • HSHP $12.66
  • ADCT N/A
  • Revenue Growth
  • HSHP 919.64
  • ADCT N/A
  • 52 Week Low
  • HSHP $4.51
  • ADCT $0.36
  • 52 Week High
  • HSHP $9.76
  • ADCT $6.04
  • Technical
  • Relative Strength Index (RSI)
  • HSHP 47.33
  • ADCT 46.44
  • Support Level
  • HSHP $6.79
  • ADCT $2.81
  • Resistance Level
  • HSHP $7.21
  • ADCT $3.30
  • Average True Range (ATR)
  • HSHP 0.17
  • ADCT 0.18
  • MACD
  • HSHP 0.06
  • ADCT 0.00
  • Stochastic Oscillator
  • HSHP 76.40
  • ADCT 23.47

About HSHP Himalaya Shipping Ltd.

Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Share on Social Networks: